Triple-negative breast cancer(TNBC)remains the most aggressive cluster of all breast cancers,which is due to its rapid progression,high probabilities of early recurrence,and distant metastasis resistant to standard treatment.Following the advances in cancer genomics and transcriptomics that can illustrate ...
Xuebing Shi,Lu Wang.Treatment for triple-negative breast cancer[J]. The Chinese-German Journal of Clinical Oncology .2012(9)Treatment for triple-negative breast cancer[J] . Xuebing Shi,Lu Wang.The Chinese-German Journal of Clinical Oncology . 2012 (9)Shi XB;Wang L.Treatment for triple-...
The key role of immune-checkpoint inhibitors in the treatment of TNBC is being defined and a plethora of ongoing trials testing different combination approaches will provide additional insights to improve the efficacy of immunotherapy. The application of a breast cancer immunogram describing the TNBC ...
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as ...
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment by Domiziana Masci 1, Chiara Naro 2,3, Michela Puxeddu 4, Andrea Urbani 1, Claudio Sette 2,3, Giuseppe La Regina 4 and Romano Silvestri 4,* 1 Department of Basic Biotechnological Sciences, Intensivologica...
Triple-negative breast cancer is more aggressive than other forms. It’s more likely to have spread beyond your breast at the time it’s found, and there’s a higher chance it will come back within the first 3 years after treatment. It’s also more likely to be fatal within the first...
The study could lead to new treatment strategies for patients with triple-negative breast cancer, including targeting NAC1 to kill the root of cancer, and restore the immune system's ability to recognize and fight cancer cells. This study's findings are particularly significant becausetriple-negativ...
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Triple-negative breast cancer is an aggressive subtype of breast cancer that has limited treatment options when it does not respond to or progresses following standard anthracycline- and/or taxane-containing regimens. Research is now directed at identifying molecules that may be effective targets for ...
selective FGFR inhibitor AZD4547 [116]. But a study demonstrated that only 1 in 8 breast cancer patients with FGFR1 amplification responded to AZD4547 treatment. These data suggest that FGFR targeting has shown promising results in breast cancer, especially when FGFR is amplified [117] (Fig.3)...